DCL will adopt products from Third Wave’s expanding molecular diagnostic menu and have early access to new assays and equipment developed by Third Wave. Third Wave will establish a research and development laboratory at DCL for joint product research, which will include a customer demonstration facility for Third Wave products.
Michael Hanbury, president and CEO of DCL, said: “Partnering with Third Wave extends DCL’s capabilities as an interventional anatomic pathology team with experienced development and clinical trial services that target the pharmaceutical and medical device industries.”